RESUMO
【Objective】 To systematically evaluate the therapeutic efficacy of autologous platelet-rich plasma combined with negative pressure wound therapy on chronic refractory wounds, and to provide reference for clinical treatment. 【Methods】 Randomized controlled trials of autologous platelet-rich plasma combined with negative pressure wound therapy for the treatment of chronic refractory wounds were included in the databases of CNKI, Wan fang, VIP, PubMed, Embase and Cochrane Library from the time of database construction to November 2022. After literature screening, data extraction and quality evaluation, Meta analysis was performed using Stata 15.1 software. 【Results】 After screening, a total of 11 Chinese literatures that met the criteria of this paper were retrieved, involving a total of 359 patients with chronic refractory wounds. The observation group was treated with autologous platelet-rich plasma combined with negative pressure wound therapy, and the control group was treated with negative pressure wound therapy alone. Meta-analysis suggested that compared with negative pressure wound therapy alone, autologous platelet-rich plasma combined with negative pressure wound therapy shortened wound healing time [WMD=-6.08, 95%CI (-7.77, -4.40), P<0.05]. The hospitalization was shortened [WMD=-8.24, 95%CI (-11.55, -4.94), P<0.05], the pain score was decreased [WMD=-1.73, 95%CI (-2.06, -1.40), P<0.05], and the positive rate of bacterial culture on the wound was decreased [RR=0.28, 95%CI(0.16, 0.49), P<0.05], the wound treatment effect was good [RR=1.28, 95%CI(1.17, 1.41), P<0.05]. 【Conclusion】 Based on current studies, compared with the negative pressure wound therapy alone, autologous platelet-rich plasma combined with negative pressure wound therapy can effectively promote the healing of chronic refractory wounds, shorten the hospital stay, reduce pain and infection, and the clinical treatment effect is better.
RESUMO
【Objective】 To explore the mechanism of testosterone on eryptosis. 【Methods】 The erythrocyte suspension (1%) was cultured in vitro and divided into 3 groups: 2 kinds of eryptosis models induced by hydrogen peroxide (H2O2) in vitro, 3×10-8 mol/L testosterone + 200 μmol/L H2O2 group (group A), 200 μmol/L H2O2 treatment group (group B) and 1×PBS buffer control group (group C). Erythrocytes were collected from 12 well plates (about 2×106/well) at 24 h and 60 h to detect the eryptosis rate, intracellular ROS and [Ca2+ ]i through flow cytometry, and the changes of each index were analyzed by t test. 【Results】 The eryptosis rate(%)at 24 h and 60 h in group A, B and C were 2.61±0.28, 11.25±1.43 vs 7.15±0.95, 28.65±0.74 vs 1.32±0.07, 8.18±0.08 (P<0.01); ROS level(%): 14.52±0.68, 15.26±0.49 vs 16.68±0.60, 21.68±1.10 vs 7.61±0.21, 10.29±1.06 (P<0.01); [Ca2+ ]i(%): 6.54±0.46, 8.93±0.87 vs 11.78±0.76, 14.63±0.80 vs 1.36±0.20, 2.44±0.38 (P<0.01). The eryptosis rate, ROS level and [Ca2 + ]i in group A were significantly lower than those in group B (P<0.01). 【Conclusion】 Testosterone effectively inhibits eryptosis induced by H2O2 in vitro and its mechanism may be related to reducing ROS production and maintaining normal [Ca2+ ]i.
RESUMO
Objective@#To evaluate the expression of OCT4 and SALL4 in testicular diffuse large B-cell lymphoma (DLBCL), and the utility of an immunohistochemical (IHC) panel of OCT4, SALL4 and CD20 in the differential diagnosis of DLBCL and GCT of the testis.@*Methods@#Eighteen cases of testicular DLBCL were selected.IHC method was used to detect the protein expression of CD20, CD3, CD5, CD10, bcl-6, MUM1, Ki-67, bcl-2, c-MYC, OCT4 and SALL4.@*Results@#Among the 18 cases, CD20 and PAX5 were strongly and diffusely expressed in all cases, while CD21, CD3, cyclinD1, SALL4, CD117 and PLAP were all negative. CD5, bcl-2 and c-myc were expressed in 3, 16 and 8 cases, respectively. Ki-67 proliferation index ranged from 40%-95%. Bcl-2 and c-MYC were co-expressed in seven cases. Four cases were GCB-DLBCL and the remaining 14 cases were non-GCB-DLBCL, according to Hans algorithm. Nuclear OCT4 expression was present in two cases, which demonstrated moderate expression in >50% of neoplastic cells. Univariate analysis showed that clinical stage, CD5 and OCT4 expression were relevant to prognosis. Multivariate Cox regression analysis further confirmed that clinical stage, CD5 and OCT4 were independent prognostic factors in patients with testicular DLBCL.@*Conclusions@#Care should be exercised in using OCT4 as the sole marker of germ cell differentiation in the testis. The association of OCT4 and CD5, bcl-2 co-expression raises the question of whether OCT4 expression in DLBCL may reflect more aggressive biology.